AvenCell gets $112M to build switchable CAR-T therapies for ‘the last frontier’ of blood cancers

Lei Lei Wu

News Reporter

AvenCell Therapeutics on Tuesday said it collected $112 million to continue clinical studies of two experimental acute myeloid leukemia CAR-T cell therapies.

The Series B …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AvenCell gets $112M to build switchable CAR-T therapies for ‘the last frontier’ of blood cancers

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Aven­Cell gets $112M to build switch­able CAR-T ther­a­pies for ‘the last fron­tier’ of blood can­cers

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

AvenCell gets $112M to build switchable CAR-T therapies for ‘the last frontier’ of blood cancers